We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Jens Hennecke Joins Delenex Therapeutics AG
News

Jens Hennecke Joins Delenex Therapeutics AG

Jens Hennecke Joins Delenex Therapeutics AG
News

Jens Hennecke Joins Delenex Therapeutics AG

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Jens Hennecke Joins Delenex Therapeutics AG"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Delenex Therapeutics AG has announced that it has engaged Jens Hennecke, PhD, as Business and Corporate Development Advisor.

Dr. Jens Hennecke (46) has a strong track record in business development, corporate development and licensing. He brings extensive experience in the negotiation and closing of corporate alliances.

Prior to joining Delenex and building his own business development advisory franchise, he held the position of Senior Vice President Business Development at Micromet, Inc. where he played a key role in establishing partnerships with major pharma companies, as well as in Micromet’s acquisition by Amgen in 2012.

Dr. Hennecke holds a B.Sc. in biology from the University of Göttingen, Germany, and a Ph.D. from the ETH Zurich, Switzerland.

Dr. Thomas Hecht, Executive Chairman of Delenex mentioned, “We are pleased and proud to have attracted Jens with his international experience and strong business development and licensing background. We are convinced that Jens will add to the success of Delenex and spearhead our business development activities to add new partnerships.”

“I am very much looking forward to working with Delenex,” said Dr. Jens Hennecke. “Delenex has a strong pipeline of PENTRA®Bodies and advanced clinical projects, including topical treatments of dermatologic diseases. This provides for significant partnering opportunities beyond Novartis’ exclusive use of the platform for ophthalmic diseases.”

Advertisement